Bear of the Day: Quest Diagnostics (DGX)

Quest Diagnostics (DGX) second-quarter EPS of $0.89 beats the Zacks Consensus Estimate by a penny and the year-ago quarter s by 7 cents. However, revenues declined 1.4% to $1.9 billion, driven by a decline in both volume and pricing.

Meanwhile, the company proactively negotiated contracts with some MCOs at reduced prices. Although this gives more visibility, revenue per requisition was affected in the near term. Quest is adopting strategies such as suitable acquisitions, increased sales force and targeting additional geographies to drive its top line.

However, we believe in the near term volume and pricing outlook will continue to remain under pressure unless the economic scenario improves. As a result, we lower our estimates for the company and downgrade it to Underperform.

QUEST DIAGNOSTC (DGX): Free Stock Analysis Report

About Zacks Investment Research 1766 Articles

Zacks Investment Research is one of the most highly regarded firms in the investment industry. In 1978 Zacks originated the concept of utilizing earnings estimates revisions to make profitable investment decisions. Zacks offers multiple investment products and services to help investors achieve superior returns.


Be the first to comment

Leave a Reply

Your email address will not be published.